Impact of CYP1A1 Polymorphisms on Susceptibility to Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Table 3

The results of evidence synthesis in this meta-analysis.

Variables	Dominant model				Recessive model				Homozygote comparison				Heterozygote comparison				Additive model
		OR (CI)				OR (CI)				OR (CI)				OR (CI)				OR (CI)
MspI
Total	6	1.14 (0.77, 1.70)	0.51	0.002	5	1.57 (1.09, 2.26)	0.02	0.45	5	1.73 (1.18, 2.55)	0.005	0.34	5	1.22 (0.77, 1.94)	0.4	0.002	5	1.21 (0.91, 1.60)	0.2	0.02
By ethnicity
Asian	3	1.07 (0.59, 1.92)	0.83	0.03	2	1.70 (1.06, 2.71)	0.03	0.62	2	1.84 (1.11, 3.06)	0.02	0.65	2	1.22 (0.51, 2.89)	0.65	0.03	2	1.29 (0.94, 1.78)	0.06	0.2
Caucasian	3	1.23 (0.63, 2.40)	0.55	0.002	3	1.39 (0.78, 2.48)	0.27	0.19	3	1.60 (0.89, 2.88)	0.12	0.12	3	1.24 (0.61, 2.51)	0.55	0.002	3	1.13 (0.69, 1.86)	0.62	0.008
By source of controls
PB	3	0.88 (0.69, 1.12)	0.3	0.28	3	1.48 (0.91, 2.41)	0.11	0.18	3	1.35 (0.81, 2.24)	0.25	0.27	3	0.82 (0.64, 1.07)	0.14	0.13	3	0.98 (0.80, 1.20)	0.85	0.31
HB	2	2.01 (1.40, 2.87)	0.0001	0.97	2	1.68 (0.97, 2.91)	0.06	0.61	2	2.40 (1.32, 4.36)	0.004	0.71	2	1.92 (1.32, 2.80)	0	0.92	2	1.65 (1.26, 2.14)	0.0002	0.82
By matching criteria
More than 2 items	2	1.09 (0.83, 1.44)	0.52	0.0005	2	1.73 (0.92, 3.27)	0.09	0.62	2	2.01 (1.06, 3.81)	0.03	0.28	2	1.13 (0.42, 3.05)	0.81	0.0008	2	1.17 (0.57, 2.39)	0.67	0.002
Less than 3 items	4	1.09 (0.83, 1.43)	0.55	0.07	3	1.49 (0.95, 2.33)	0.08	0.18	3	1.59 (0.98, 2.58)	0.06	0.21	3	1.29 (0.73, 2.30)	0.39	0.06	3	1.23 (0.98, 1.53)	0.07	0.38
By sample size
>300	3	1.11 (0.62, 1.96)	0.73	0.002	3	1.80 (1.16, 2.79)	0.008	0.87	3	1.84 (1.17, 2.89)	0.009	0.52	3	1.01 (0.56, 1.83)	0.97	0.002	3	1.15 (0.77, 1.72)	0.49	0.008
<300	3	1.20 (0.62, 2.33)	0.6	0.04	2	1.13 (0.58, 2.20)	0.72	0.11	2	0.96 (0.13, 7.25)	0.97	0.07	2	1.76 (1.09, 2.84)	0.02	0.63	2	1.37 (0.98, 1.92)	0.07	0.26
Ile/Val
Total	4	1.34 (0.84, 2.13)	0.21	0.04	3	2.75 (1.29, 5.84)	0.009	0.15	3	3.23 (1.50, 6.93)	0.003	0.16	3	1.39 (1.01, 1.90)	0.04	0.21	3	1.50 (0.88, 2.55)	0.13	0.02
By ethnicity
Asian	2	1.32 (0.56, 3.11)	0.52	0.04
Caucasian	2	1.34 (0.63, 2.88)	0.45	0.04	2	1.67 (0.09, 30.45)	0.73	0.07	2	1.72 (0.09, 34.41)	0.72	0.06	2	1.19 (0.81, 1.74)	0.37	0.27	2	1.41 (0.55, 3.63)	0.48	0.005
By source of controls
HB	2	1.99 (1.37, 2.90)	0.0003	0.96	2	3.48 (1.50, 8.08)	0.004	0.23	2	4.24 (1.79, 10.04)	0.001	0.36	2	1.69 (1.13, 2.51)	0.01	0.5	2	1.94 (1.43, 2.64)	0.0001	0.33
By matching criteria
More than 2 items	2	1.34 (0.63, 2.88)	0.45	0.04	2	1.67 (0.09, 30.45)	0.73	0.07	2	1.72 (0.09, 34.41)	0.72	0.06	2	1.19 (0.81, 1.74)	0.37	0.27	2	1.41 (0.55, 3.63)	0.48	0.005
Less than 3 items	2	1.32 (0.56, 3.11)	0.52	0.04
By sample size
>300	2	1.34 (0.63, 2.88)	0.45	0.04	2	1.67 (0.09, 30.45)	0.73	0.07	2	1.72 (0.09, 34.41)	0.72	0.06	2	1.19 (0.81, 1.74)	0.37	0.27	2	1.41 (0.55, 3.63)	0.48	0.005
<300	2	1.32 (0.56, 3.11)	0.52	0.04

Number of included studies in evidence synthesis.
: value of test to evaluate the significance of the ORs; : value of test for heterogeneity test.